News & Updates

Inhaled treprostinil tied to favourable outcomes in PH-ILD

11 Jun 2021 by

In post hoc analyses of the phase III INCREASE trial presented at ATS 2021, patients on inhaled treprostinil (iTre) for pulmonary hypertension due to parenchymal lung disease (PH-ILD) were less inclined to have multiple clinical worsening events and more likely to experience clinical improvement vs those on placebo.

Inhaled treprostinil tied to favourable outcomes in PH-ILD

11 Jun 2021

Secondhand smoke may up RA risk

09 Jun 2021 by

Exposure to secondhand smoke, regardless of whether it is during childhood or adulthood, is associated with an increased risk of developing rheumatoid arthritis (RA) among women — particularly in those who never smoke themselves, according to data from the E3N-EPIC study presented at the EULAR 2021 Congress.

Secondhand smoke may up RA risk

09 Jun 2021

Nintedanib may spare lung in COVID-19

09 Jun 2021 by

The antifibrotic agent nintedanib appears to help minimize lung injury in patients with severe COVID-19 undergoing mechanical ventilation, with a recent study showing that treatment lowers the likelihood of acute respiratory failure, shortens ventilation time, and reduces the volume of high-attenuation areas on imaging.

Nintedanib may spare lung in COVID-19

09 Jun 2021

Tocilizumab administration for severe COVID-19: Timing matters

09 Jun 2021 by

Early administration (ie, pre-intubation/noninvasive ventilation) of the interleukin-6 receptor blocker tocilizumab in patients with severe COVID-19 led to more favourable outcomes compared with late administration (ie, post-intubation/noninvasive ventilation), according to data presented at ATS 2021.

Tocilizumab administration for severe COVID-19: Timing matters

09 Jun 2021

COVID-19 vaccine uptake to remain low in HK due to misconceptions

07 Jun 2021 by

Uptake of coronavirus disease 2019 (COVID-19) vaccines is likely to remain low in Hong Kong, with only 25 percent of unvaccinated individuals intending vaccination in the next 6 months, according to a recent survey conducted by the Chinese University of Hong Kong (CUHK).

COVID-19 vaccine uptake to remain low in HK due to misconceptions

07 Jun 2021

COVID-19 may have gone undetected in nearly 20,000 adults in HK

07 Jun 2021 by

Almost 20,000 individuals, or about 0.3 percent of Hong Kong’s population, may have had undetected coronavirus disease 2019 (COVID-19), according to a serology study of 4,198 adults conducted by the Chinese University of Hong Kong (CUHK).

COVID-19 may have gone undetected in nearly 20,000 adults in HK

07 Jun 2021

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

06 Jun 2021 by

The specific TSLP* inhibitor tezepelumab significantly reduces exacerbation rates across a broad spectrum of patients with severe, uncontrolled asthma, regardless of the status of key inflammatory biomarkers, according to the NAVIGATOR study presented at ATS 2021.

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

06 Jun 2021

Breakthrough infections after COVID-19 vaccines: Who is at risk?

05 Jun 2021 by

While the rate of breakthrough infections is low among people who have been fully vaccinated against COVID-19, researchers found that older age and having anaemia were associated with an increased risk of such infections.

Breakthrough infections after COVID-19 vaccines: Who is at risk?

05 Jun 2021

Asthma does not compromise mental health in teens

04 Jun 2021

Asthma does not seem to hurt mental wellbeing among adolescents, though it may worsen general health, a recent study has found.

Asthma does not compromise mental health in teens

04 Jun 2021

Long-term study findings reflect potential of sotatercept for PAH

04 Jun 2021 by

The efficacy and safety of the novel, first-in-class, selective fusion protein sotatercept were sustained or enhanced for up to 48 weeks when added to standard of care (SOC) for the treatment of pulmonary arterial hypertension (PAH), according to interim findings of the ongoing open-label extension (OLE) period of the phase II PULSAR trial presented at ATS 2021.

Long-term study findings reflect potential of sotatercept for PAH

04 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Inhaled treprostinil tied to favourable outcomes in PH-ILD

Inhaled treprostinil tied to favourable outcomes in PH-ILD

Secondhand smoke may up RA risk

Secondhand smoke may up RA risk

Nintedanib may spare lung in COVID-19

Nintedanib may spare lung in COVID-19

Tocilizumab administration for severe COVID-19: Timing matters

Tocilizumab administration for severe COVID-19: Timing matters

COVID-19 vaccine uptake to remain low in HK due to misconceptions

COVID-19 vaccine uptake to remain low in HK due to misconceptions

COVID-19 may have gone undetected in nearly 20,000 adults in HK

COVID-19 may have gone undetected in nearly 20,000 adults in HK

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

Breakthrough infections after COVID-19 vaccines: Who is at risk?

Breakthrough infections after COVID-19 vaccines: Who is at risk?

Asthma does not compromise mental health in teens

Asthma does not compromise mental health in teens

Long-term study findings reflect potential of sotatercept for PAH

Long-term study findings reflect potential of sotatercept for PAH